Risk factors for reactivation of clinical disease activity in multiple sclerosis after natalizumab cessation.

Mustonen, Tiina

Risk factors for reactivation of clinical disease activity in multiple sclerosis after natalizumab cessation. [electronic resource] - Multiple sclerosis and related disorders Feb 2020 - 101498 p. digital

Publication Type: Journal Article

2211-0356

10.1016/j.msard.2019.101498 doi


Adrenal Cortex Hormones--administration & dosage
Adult
Female
Follow-Up Studies
Humans
Immunologic Factors--administration & dosage
Male
Middle Aged
Multiple Sclerosis, Relapsing-Remitting--drug therapy
Natalizumab--administration & dosage
Retrospective Studies
Risk Factors
Secondary Prevention
Severity of Illness Index
Symptom Flare Up
Time Factors
Young Adult